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ABSTRACT
Objective: The study investigated the factors affecting
health-care costs and hospitalizations among diabetic
patients in Thai public hospitals.
Methods: A retrospective study was conducted by using
administrative claims data obtained from diabetic patients
during October 1, 2002 and September 30, 2003. Dependent
variables were total health-care costs and the occurrence of
hospitalizations. Independent variables included demogra-
phic factors, health-care utilizations, complications, comor-
bidities, and payment methods. Multivariate statistical
analyses were applied.
Results: The results of this study suggested that demographic
factors of patients (i.e., age and male sex), payment methods
(i.e., capitation, fee-for-service, and out-of-pocket) were sig-
niﬁcantly associated with higher health-care costs and prob-
ability of hospitalization. Patients receiving treatment from
teaching hospitals signiﬁcantly consumed higher health-care
costs. In addition, the more health-care utilizations (i.e.,
occurrence of hospitalization, number of outpatient visit,
and insulin utilization), the higher health-care costs the
patients signiﬁcantly had. Diabetic patients taking insulin
had signiﬁcantly higher health-care costs and risk of hospi-
talization. Furthermore, comorbidities (e.g., hypertension
and cancer) and diabetes-related complications (e.g., nephr-
opathy, neuropathy, retinopathy, coronary artery disease,
cardiovascular disease, and peripheral vascular disease) were
signiﬁcantly associated with an increase in health-care costs
and hospitalization.
Conclusion: Factors affecting health-care costs and hospital-
izations may help health-care providers intervene to improve
patient management and possibly reduce health-care costs in
the future.
Keywords: diabetes, health-care costs, hospitalizations, risk
factors.
Introduction
Diabetes is a common, serious, and chronic disease
causing major long-term complications and comor-
bidities. For all age groups worldwide, the prevalence
of diabetes was estimated at 2.8% in 2000 and 4.4%
in 2030 [1]. Especially in the economically developing
countries, it is predicted to have the greatest increase
[2]. Among Thai people, the prevalence of diabetes
was estimated at 2.4% in 1995 and 3.5% in 2025 [2].
The rise in prevalence of diabetes leads to an increase
in prevalence of diabetic complications (e.g., retinopa-
thy [23%], nephropathy [24%], amputation [1.6%],
coronary disease [8.2%], and stroke [4.4%]) and dia-
betic comorbidities (e.g., hypertension [63.6%] and
dyslipidemia [73.3%]) [3]. Diabetic-related complica-
tions and comorbidities largely affect patient outcomes
and health-care costs. In the United States, the total
cost of diabetes was $132 billion (i.e., direct [69.7%]
and indirect cost [30.3%]) [4]. In Thailand, there have
been few studies estimating the cost of diabetes. Based
on the study determining the costs of patients with
diabetes in seven Thai government hospitals located
in four regions of Thailand and Bangkok, the annual
average direct medical cost per diabetic patient was
6017 baht, which was signiﬁcantly higher than those
without diabetes [5]. In addition, the annual average
total health-care cost per diabetic patient was 13,751
baht (i.e., direct medical and nonmedical cost
[82.26%] and indirect cost [17.74%]) [6]. The average
direct medical cost per outpatient visit was about 1206
baht per diabetic patient [7]. Recently, seven studies
performed in the United States or Taiwan have inves-
tigated the impact of factors such as demographic
characteristics, number of diabetic complications, num-
ber of health-care utilization, length of stay (LOS),
and payment methods on health-care costs or hospital-
izations [8–14]. In Thailand, only two studies have
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determined the factors associated with direct medical
costs, but no study has ever investigated the association
between factors and the occurrence of hospitalization
[6,15]. Therefore, the objective of this study was to
investigate the factors associated with total health-care
costs and the occurrence of hospitalization. Knowledge
of these factors may help health-care providers inter-
vene to improve patient management and possibly
reduce health-care costs in the future.
Methods
Data Source
A retrospective study was conducted by using admin-
istrative databases obtained from four Thai govern-
ment hospitals during October 1, 2002 and September
30, 2003. These data were allowed to be used in this
study by hospital administrators. Data included demo-
graphic characteristics, medical history of illness,
health-care utilizations, and medical costs. Medical
cost data were all charges of patients’ underpayment
methods such as capitation (i.e., social security scheme
[SSS] and universal coverage [UC]), fee-for-service
(FFS) (i.e., civil servant medical beneﬁts scheme
[CSMBS]), and out-of-pocket. The social security
ofﬁce pays a ﬁxed amount of money per year to hos-
pitals for covering health-care beneﬁts of employees
who enrolled under SSS. Under CSMBS, the govern-
ment provides full health-care coverage for govern-
ment ofﬁcers and their dependents (e.g., parents,
spouse, and up to three children). Regarding the UC,
the national health security ofﬁce pays a ﬁxed amount
of money per year to hospitals for covering health-care
beneﬁts of patients who enrolled under UC, and
patients also pay 30 baht per visit ($US 1 = 35 baht)
[16]. Out-of-pocket means that patients pay all health-
care costs by themselves. Although patients under
capitation payment method did not actually pay for
their total charges, their medical charge data were still
recorded on hospitals’ databases.
Patient Selection
Diabetic patients must have at least one claim with the
primary, secondary, or tertiary diagnostic code of dia-
betes mellitus based on the International Statistics
Classiﬁcation Diagnostics and Health Problem tenth
revision (ICD-10 codes = E10-E14).
Statistical Analysis
Data were transformed to a patient-level or cross-
sectional data. Univariate and multivariate statistical
analyses (i.e., ordinary least square (OLS) regression
and logistic regression analyses) were applied. SPSS
program version 11.0 was used for statistical analy-
ses. Multiple linear regression analysis and log trans-
formation were used when a dependent variable
was total health-care costs. Total health-care costs
were the summation costs of both diabetic and
nondiabetic-related resource use (e.g., drugs, medical
supplies, laboratory tests, surgeries, hospitalizations,
and other health-care services) incurred by patients
with diabetes. Logistic regression analysis was applied
when the occurrence of hospitalization was a depen-
dent variable. Nevertheless, the occurrence of hospi-
talization was used as one of independent variables
when a dependent variable was total health-care
costs. Other independent variables included demo-
graphic factors (e.g., age, female), payment methods
such as capitation (i.e., SSS and UC), FFS (i.e.,
CSMBS), and out-of-pocket, hospital characteristics
(e.g., teaching hospital), health care and drug utiliza-
tions (e.g., outpatient visits and insulin utilization),
comorbidities (e.g., hypertension, hyperlipidemia, and
cancer), microvascular complications (e.g., retinopa-
thy, nephropathy, and neuropathy), and macrovas-
cular complications (e.g., coronary artery disease
[CAD], cardiovascular disease [CVD], and peripheral
vascular disease [PVD]). Comorbidities and complica-
tions were identiﬁed by ICD-10 codes. All variables
used in the analysis and the reference categories of
dummy variables are presented in Table 1.
Table 1 Variables used in the analysis
Variables Type (reference category)
Dependent variables
Health-care costs Continuous (baht)
Hospitalization Dummy (yes = 1, no = 0)
Independent variables
Demographics:
Age Continuous (years)
Female Dummy (female = 1, male = 0)
Payment method:
Capitation (i.e., SSS or UC) Dummy (yes = 1, no = 0)
FFS (i.e., CSMBS) Dummy (yes = 1, no = 0)
Out-of-pocket Dummy (yes = 1, no = 0)
Hospital characteristics:
Teaching hospital Dummy (teaching hospital = 1,
nonteaching hospital = 0)
Health-care utilization:
Number of outpatient visits Continuous
Insulin utilization Dummy (insulin users = 1,
noninsulin users = 0)
Comorbidity:
Hypertension Dummy (yes = 1, no = 0)
Hyperlipidemia Dummy (yes = 1, no = 0)
Cancer Dummy (yes = 1, no = 0)
Microvascular complications:
Retinopathy Dummy (yes = 1, no = 0)
Nephropathy Dummy (yes = 1, no = 0)
Neuropathy Dummy (yes = 1, no = 0)
Macrovascular complications:
CAD Dummy (yes = 1, no = 0)
CVD Dummy (yes = 1, no = 0)
PVD Dummy (yes = 1, no = 0)
CAD, coronary artery disease; CVD, cardiovascular disease; CSMBS, civil servant
medical beneﬁts scheme; FFS, fee-for-service; PVD, peripheral vascular disease; SSS,
social security scheme; UC, universal coverage.
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Results
Table 2 shows the results of the descriptive statistics of
the sample. There were 24,051 patients with diabetes
with average age of 59 years old (standard deviation
[SD] 13.14). Sixty-six percent of patients with diabetes
were female and 99%had type II diabetes. In this study,
diabetic patients were under capitation (34%) (i.e., SSS
[6%] and UC [28%]), FFS (i.e., CSMBS [19%]), and
out-of-pocket (47%). Moreover, 61% of patients
received their treatment at teaching hospitals. The
average annual total health-care cost per person was
19,299 baht or $551 (SD 64,754 baht or $1,850). The
median annual total health-care cost per person was
5,658 baht or $162 (Interquartile Range, IQR =
14,209 baht or $406). The annual LOS per person was
2.52 (SD 9.10) days. The average annual number of
hospitalizations per person was 0.35 (SD 0.89), and the
average annual number of outpatient visits per person
was 7.39 (SD 6.20). In this analysis, there were 77% of
patients who had only outpatient visits. Only 21% of
patients were admitted to the hospitals and the average
annual number of hospitalizations per person of these
patients was 1.63 (SD 1.26), whichwas higher than that
of total patients (0.35 [SD 0.89]). In addition, 12% of
diabetic patients took insulin.
Tables 3 and 4 shows the results of OLS and logis-
tic regression analyses, respectively. Age (parameter
Table 2 Descriptive statistics of the sample
Variables
Statistical values
(N = 24,051)
Demographics:
Average age (years) 59 (SD = 13.14)
Female sex 66%
Type II diabetes 99%
Payment method:
Fee-for-service
Civil servant medical beneﬁt scheme 19%
Capitation 34%
Universal coverage 28%
Social security scheme 6%
Out-of-pocket 47%
Hospital characteristics:
Number of patients in teaching hospitals 61%
Number of patients in nonteaching hospitals 39%
Health-care costs and utilization:
Average annual cost per person (baht) 19,299 baht or $551
(SD = 64,754 baht
or $1850)
Median annual cost per person (baht) 5658 baht or $162
(IQR = 14,209 baht
or $406)
Average annual length of stay per person
(day)
2.52 (SD = 9.10)
Average annual number of hospitalizations
per person
0.35 (SD = 0.89)
Average annual number of outpatient visits
per person
7.39 (SD = 6.20)
Number of patients with only outpatient
visits
77%
Number of patients admitted to hospitals 21%
Average annual number of hospitalizations
per person
1.63 (SD = 1.26)
Insulin utilization:
Number of diabetic patients taking insulin 12%
Comorbidity:
Number of diabetic patients with coronary
artery diseases
6.15%
Number of diabetic patients with
cardiovascular diseases
1.46%
Number of diabetic patients with peripheral
vascular diseases
0.59%
Number of diabetic patients with
hyperlipidemia
12.79%
Number of diabetic patients with
hypertension
33.33%
Number of diabetic patients with cancer 4.10%
Complication:
Number of diabetic patients with
nephropathy
1.77%
Number of diabetic patients with neuropathy 3.95%
Number of diabetic patients with retinopathy 8.67%
Table 3 Results of multiple linear regression analysis
Dependent variable = log of total health-care costs
Independent variables Parameter estimates P-value
Age 0.006 <0.001*
Female -0.019 0.002*
Capitation 0.083 <0.001*
Fee-for-service 0.211 <0.001*
Out-of-pocket 0.057 <0.001*
Teaching hospital 0.359 <0.001*
Hospitalization 0.615 <0.001*
Outpatient visit 0.041 <0.001*
Insulin utilization 0.344 <0.001*
Hypertension 0.096 <0.001*
Hyperlipidemia 0.029 0.002*
Cancer 0.154 <0.001*
Nephropathy 0.016 <0.001*
Neuropathy 0.064 <0.001*
Retinopathy 0.035 <0.001*
Coronary artery disease 0.141 <0.001*
Cardiovascular disease 0.058 0.024*
Peripheral vascular disease 0.213 <0.001*
*Statistically signiﬁcant at P < 0.05.
Model signiﬁcant at P < 0.001;Adjusted R-square = 0.54.
Table 4 Results of logistic regression analysis
Dependent variable = occurrence of hospitalization (yes = 1)
Independent variables Parameter estimates Odds ratio P-value
Female -0.116 0.89 0.006*
Capitation 2.163 8.69 <0.001*
FFS 2.365 10.64 <0.001*
Out-of-pocket 1.502 4.49 <0.001*
Teaching hospital -1.600 0.20 <0.001*
Outpatient visit -0.029 0.97 <0.001*
Insulin utilization 1.308 3.70 <0.001*
Hypertension 0.751 2.12 <0.001*
Hyperlipidemia 0.027 1.03 0.687
Cancer 1.525 4.60 <0.001*
Nephropathy 2.845 17.21 <0.001*
Neuropathy 1.790 5.99 <0.001*
Retinopathy 0.523 1.69 <0.001*
CAD 1.964 7.13 <0.001*
CVD 0.324 1.38 0.024
PVD 1.233 3.43 <0.001*
*Statistically signiﬁcant at P < 0.05; Model signiﬁcant at P < 0.001.
CAD, coronary artery disease; CVD, cardiovascular disease; FFS, fee-for-service; PVD,
peripheral vascular disease.
Factors and Cost of Thai Diabetic Patients S71
estimates [PE] = 0.006, P < 0.001) or male sex
(PE = -0.019, P < 0.002) had a signiﬁcant impact on
an increase in health-care costs. Payment methods
(e.g., capitation [PE = 0.083, P < 0.001], FFS
[PE = 0.211, P < 0.001], and out-of-pocket [PE =
0.057, P < 0.001]) had a signiﬁcant positive effect on
an increase in health-care costs. In addition, diabetic
patients under capitation (PE = 2.163, odds ratio
[OR] = 8.69, P < 0.001), FFS (PE = 2.365, OR =
10.64, P < 0.001) were more likely to have higher
hospitalizations compared to those paid by out-of-
pocket (PE = 1.502, OR = 4.49, P < 0.001). Diabetic
patients receiving treatment from a teaching hospital
had signiﬁcantly higher health-care costs (PE = 0.359,
P < 0.001), but they were less likely to have hospital-
izations (PE = -1.600, OR = 0.20, P < 0.001).
Patients admitted to hospital (PE = 0.615,
P < 0.001) were signiﬁcantly associated with an
increase in health-care costs. Patients with more
outpatient visits signiﬁcantly consumed higher health-
care costs (PE = 0.041, P < 0.001). Insulin users sig-
niﬁcantly had higher health-care costs (PE = 0.344,
P < 0.001) and were about four times more likely to
have hospitalizations compared to noninsulin users
(PE = 1.308, OR = 3.70, P < 0.001).
Diabetic patients with comorbidities (e.g., hyperten-
sion [PE = 0.096, P < 0.001]), hyperlipidemia (PE =
0.029, P = 0.002), and cancer (PE = 0.154, P < 0.001)]
had signiﬁcantly higher health-care costs than those
without comorbidities. In addition, diabetic patients
with hypertension (PE = 0.751, OR = 2.12, P < 0.001)
or cancer (PE = 1.525,OR = 4.60, P < 0.001) alsowere
about two or four times more likely to hospitalize
compared to those without hypertension or cancer,
respectively. Nevertheless, there was no statistical sig-
niﬁcant association between an increase in risk of hos-
pitalization and having hyperlipidemia (PE = 0.027,
OR = 1.03, P < 0.687). Furthermore, patients with
microvascular complications (e.g., nephropathy [PE =
0.016, P < 0.001]), neuropathy (PE = 0.064, P <
0.001), and retinopathy (PE = 0.035, P = 0.001)] had a
positive impact on health-care costs. Especially, diabetic
patients with nephropathy (PE = 2.845, OR = 17.21,
P < 0.001), neuropathy (PE = 1.790, OR = 5.99, P <
0.001), or retinopathy (PE = 0.524, OR = 1.69, P <
0.001) were about 18, 6, or 2 times more likely to have
hospitalizations than those without microvascular
complications, respectively. Diabetic patients with
macrovascular complications (e.g., CAD [PE = 0.141,
P < 0.001]), CVD (PE = 0.058, P = 0024), and PVD
(PE = 0.213, P < 0.001)] were positively associated
with higher health-care costs. In addition, diabetic
patients with CAD (PE = 1.964, OR = 7.13, P <
0.001), CVD (PE = 0.325, OR = 1.38, P < 0.001), or
PVD (PE = 1.223, OR = 3.39, P < 0.001) were 7, 1, or
3 times more likely to hospitalize compared to those
without CAD, CVD, or PVD, respectively. Multiple
linear and logistic regression models were signiﬁcant
(P < 0.001) and the adjustedR2 was 54%,meaning that
all signiﬁcant factors in the model were able to explain
54% of the variation in total health-care costs.
Discussion
The results of this study suggested that demographic
factors, payment methods, hospital characteristics,
health-care utilizations, comorbidities, and complica-
tions were signiﬁcantly associated with higher health-
care costs and hospitalizations. All previous studies
supported the ﬁnding that older age patients had
higher health-care costs and hospitalizations [8–15].
Moreover, male patients were more likely to have
higher costs and hospitalizations than female patients.
Krop et al. [8] found the same result, whereas the
study of Bhattacharyya [11] showed that female
patients were more likely to consume higher health-
care costs and utilization.
Regarding the payment methods, particularly
patients under FFS (i.e., CSMBS) or capitation (i.e.,
SSS or UC) signiﬁcantly had higher health-care costs
and hospitalizations compared to those paid by out-
of-pocket. In contrast to previous studies, there was no
impact of payment method factor on health-care costs.
Whether patients were enrolled in the FFS or capita-
tion systems did not have any signiﬁcant effect on the
total direct costs of diabetes [10,12]. In addition, there
was no statistically signiﬁcant difference in patients
under FFS plan on hospitalization use [11]. In this
study, it could be explained that because all health-care
costs of patients under FFS were covered by the gov-
ernment and patients under capitation would pay only
some amount of copay for their health-care costs, these
patients could easily acquire their treatments as much
as they needed and would not be worried about the
affordability of health-care expenses. Therefore, they
tended to consume higher health-care costs and hospi-
talizations. This could suggest that patient’s eligible
beneﬁts could be an important indicator of health-care
cost drivers in patients with diabetes in Thailand. Most
patients under SSS were the working-age adults who
were likely to be healthier than the patients under UC,
so that they tended to consume less health-care costs
and hospitalizations.
For hospital characteristic factor (e.g., teaching
hospitals), patients receiving treatment from teaching
hospitals signiﬁcantly consumed higher health-care
costs but had less probability of hospitalization. This
could explain that most patients with higher disease
severity from nonteaching hospitals were usually
referred to a teaching hospital. These patients mostly
had only outpatient visits and might not be able to
admit to a teaching hospital due to the lack of space.
The results reveal that more patients receiving treat-
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ment at a teaching hospital had only outpatient visits
(86%) compared to those receiving treatment at non-
teaching hospitals (61%). In addition, there were
fewer patients admitted to teaching hospital (11%)
compared to those admitted to nonteaching hospitals
(37%).
The results show that the more health-care utiliza-
tions (e.g., hospitalization, outpatient visit, and insulin
utilization), the higher health-care costs the patients
signiﬁcantly had. Moreover, diabetic patients taking
insulin had signiﬁcantly higher risk of hospitalization.
Similar results were also found in the studies of Bhat-
tacharyya [11] and Guo et al. [14].
Furthermore, diabetic patients with comorbidities
(e.g., hypertension, hyperlipidemia, and cancer) had
signiﬁcantly higher health-care costs, and diabetic
patients with hypertension or cancer tended to have
higher hospitalizations. Patients with diabetes and
microvascular complications (e.g., nephropathy, neur-
opathy, and retinopathy) had signiﬁcantly higher
health-care costs and hospitalizations. Diabetic
patients with macrovascular complications (e.g., CAD,
CVD, and PVD) had signiﬁcantly higher health-care
costs and hospitalizations. Similar to the studies of
Bhattacharyya [11] and Bhattacharyya and Else [12],
diabetic complications (e.g., retinopathy, nephropathy,
and neuropathy) and comorbidities (e.g., hyperten-
sion, hyperlipidemia, CAD, and CVD) also had a sig-
niﬁcant positive impact on health-care costs and
hospitalizations.
Two limitations have been addressed in this study.
First, the administrative claims data used might be
limited. In Thailand, there has been no standardized
claims data collection system and standardized data
coding excluding ICD-10 codes across hospitals yet, so
that different hospitals have different types of claims
data collected and data coding. This study used the
claims data obtained from four public hospitals and
combined into one data set, therefore, unmatched vari-
ables were not able to be used for the analysis. Some
different coding of administrative claims data would
not allow us to identify which type of health-care cost
was either diabetic or nondiabetic-related treatment.
Thus, in this study, all health-care costs consumed by
patients with diabetes were used instead of the costs
related to diabetic-related treatment only. Last, like
any other retrospective claims data analysis, clinical
information such as blood glucose level and other
laboratory values would have been highly associated
with health-care costs and hospitalizations. Without
these clinical measures, assessing the perfect associa-
tion between factors and health-care costs and hospi-
talizations might not be possible. Nevertheless, the
ﬁnding may still be useful information for health-care
providers and health policymakers because signiﬁcant
factors in this analysis were able to explain 54% of the
variation in total health-care costs.
Based on the results of this study, it is suggested
that health-care providers and health policymakers
may need to focus on the factors associated with an
increase in health-care costs and hospitalizations,
such as patients with older age, male sex, comorbidi-
ties, complications, patients under capitation or FFS
system, and patients taking insulin. Health-care pro-
viders may set up the interventions such as diabetic
patient counseling, pharmaceutical care, or disease
management to delay the progression of comorbidi-
ties or complications that diabetic patients may pos-
sibly have in the future [17,18]. Although patients
under capitation or FFS system have signiﬁcantly
higher health-care costs and hospitalization, these
patients may not be at risk. This factor signals the
eligible beneﬁts rather than the potential prognostic
factors of health-care costs and utilizations. This may
relatively indicate the issue of inequity in health care
rather than disease severity. It may be used as the
information for health policymakers to solve the ineq-
uity problem. An investigation of factors associated
with health-care costs and hospitalizations may help
health-care providers and administrators intervene to
improve patient management and possibly reduce
health-care costs in the future.
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